Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles
| Autor: | Anwar R. Padhani, N C Levitt, S Mehta, N P Hughes, Sonia P. Li, Andreas Makris, R F Adams, A Adwani, Francesca M. Buffa, NJ Taylor, Adrian L. Harris |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Gadolinium DTPA
Vascular Endothelial Growth Factor A Oncology Cancer Research medicine.medical_specialty Pathology Bevacizumab Contrast Media Angiogenesis Inhibitors Breast Neoplasms Antibodies Monoclonal Humanized 03 medical and health sciences 0302 clinical medicine Breast cancer Predictive Value of Tests Internal medicine Antineoplastic Combined Chemotherapy Protocols Gene expression Biomarkers Tumor medicine Medical imaging Humans 030304 developmental biology 0303 health sciences medicine.diagnostic_test business.industry Gene Expression Profiling Biopsy Needle Cancer Magnetic resonance imaging General Medicine medicine.disease Magnetic Resonance Imaging Neoadjuvant Therapy 3. Good health Gene Expression Regulation Neoplastic Gene expression profiling Receptors Vascular Endothelial Growth Factor Treatment Outcome Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female Primary breast cancer business medicine.drug |
| Zdroj: | JNCI Monographs |
| ISSN: | 1745-6614 1052-6773 |
| DOI: | 10.1093/jncimonographs/lgr027 |
| Popis: | Antiangiogenic therapy is a promising approach for the treatment of breast cancer. In practice, however, only a subset of patients who receive antiangiogenic drugs demonstrate a significant response. A key challenge, therefore, is to discover biomarkers that are predictive of response to antiangiogenic therapy. To address this issue, we have designed a window-of-opportunity study in which bevacizumab is administered as a short-term first-line treatment to primary breast cancer patients. Central to our approach is the use of a detailed pharmacodynamic assessment, consisting of pre- and post-bevacizumab multi-parametric magnetic resonance imaging scans and core biopsies for exon array gene expression analysis. Here, we illustrate three intrinsic patterns of response to bevacizumab and discuss the molecular mechanisms that may underpin each. Our results illustrate how the combination of dynamic imaging data and gene expression profiles can guide the development of biomarkers for predicting response to antiangiogenic therapy. J Natl Cancer Inst Monogr 2011;43:71–74 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|